InvestorsHub Logo
Followers 0
Posts 1503
Boards Moderated 0
Alias Born 09/02/2012

Re: TheFinalCD post# 6

Wednesday, 06/22/2016 4:44:44 AM

Wednesday, June 22, 2016 4:44:44 AM

Post# of 3545
Pulmatrix Named "Stock of the Year 2016" by Konlin Letter


SALT LAKE CITY, Utah, June 21, 2016 /PRNewswire/ --

In an interview with Stock Radio, Kuhn describes the "enormous" potential for making money in the low price sector, and calls Pulmatrix (PULM) a "fascinating" opportunity

TheStockRadio.com, which is dedicated to disseminating "real news" from growing companies, announced today that it has released an interview: http://thestockradio.com/konrad-j-kuhn-publisher-at-the-konlin-letter-3047.html with Konrad Kuhn, editor and publisher of the KonLin Letter, one of the nation's top investment newsletters covering small-cap stocks.

In the interview, Kuhn tells how he began trading in the market in his 20s-and because of his rigorous technical analyses, made money right from the start. In 1982, he launched his newsletter. But he really made his mark in 1987 when he correctly predicted that the 1987 market plunge would be a temporary aberration, not a devastating recession.

Most important, he focused on small-cap stocks. "We really, really like the small stock sector," Kuhn explains. "It is rough. It is hard. But you can make an enormous amount of money in the low price stock sector by using technical analysis." Buy a stock at $1 and if it goes up just $1 or $2 more, you've doubled or tripled your money. "The biggest percentage gainers have been in the small cap sector," he says.

In his newsletter, Kuhn gives expert advice on market trends. "We have over 100 indicators that we follow on the market daily," he says.

He also names what he calls the "#1 Stock Pick of the Year."

This year, his pick is Boston area-based Pulmatrix, Inc. (PULM).

"We think this is a fascinating company, for more reasons than one," he explains in the Stock Radio interview. "PULM is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. It is focused on treatments for rare diseases, including cystic fibrosis, with substantial unmet medical needs." Its innovative technology allows virtually any type of drug to be easily carried deep into the lungs to treat those conditions, Kuhn says.

Moreover, he points out, Pulmatrix is partnering with pharmaceutical giant Mylan Labs to co-develop a branded generic version of an already approved inhaled drug for chronic obstructive pulmonary disease (COPD). "The future, on a small little company like this, is enormous," he says. He predicts that once the company's stock rises above $3.50, "we could see a doubling to $8.50 to $9."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PULM News